Poltreg S.A. Logo

Poltreg S.A.

Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.

PTG | WAR

Overview

Corporate Details

ISIN(s):
PLPLTRG00012 (+2 more)
LEI:
259400XSAJTERJ42VZ86
Country:
Poland
Address:
GDAŃSK BOTANICZNA 20, 80-298 GDAŃSK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Poltreg S.A. is a clinical-stage biotechnology company pioneering the development of T-regulatory cell (Treg) therapies for autoimmune diseases. The company aims to establish Tregs as a new class of disease-modifying therapeutics. Its advanced pipeline features several clinical assets, with the lead candidate, PTG-007, being developed for Type-1 Diabetes and Multiple Sclerosis (MS). Poltreg is also advancing engineered cell therapies, including first-in-class CAR-Treg programs for MS and Amyotrophic Lateral Sclerosis (ALS). Leveraging its own manufacturing facilities and extensive experience, the company was the first to administer a Treg-based therapy to a patient.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-19 17:15
Regulatory News Service
Raport kwartalny 3Q 2025
Polish 3.1 MB
2025-11-10 13:17
Regulatory News Service
Przyznanie europejskiego patentu dotyczącego metody ekspansji ex vivo limfocytó…
Polish 818 bytes
2025-11-07 09:11
Board/Management Information
Powołanie do Rady Dyrektorów Immuthera C-corp renomowanego naukowca i lidera br…
Polish 1.7 KB
2025-10-31 13:04
Major Shareholding Notification
Formularz
Polish 789.9 KB
2025-10-31 13:04
Declaration of Voting Results & Voting Rights Announcements
Zawiadomienie od TFI Allianz Polska S.A. o zmianie udziału w ogólnej liczby gło…
Polish 502 bytes
2025-09-10 17:09
Audit Report / Information
Raport biegłego rewidenta z przeglądu sprawozdania finansowego
Polish 233.4 KB
2025-09-10 17:09
Management Discussion and Analysis
Sprawozdanie Zarządu z działalności za okres 6 miesięcy zakończony dnia 30 czer…
Polish 2.8 MB
2025-09-10 17:09
Interim Report
Sprawozdanie finansowe za okres 6 miesięcy zakończony dnia 30 czerwca 2025 roku
Polish 3.4 MB
2025-09-03 10:39
Regulatory News Service
Warunkowe przyznanie patentu przez Koreański Urząd Patentowy w projekcie terapi…
Polish 1.7 KB
2025-08-04 14:37
Legal Proceedings Report
Podanie pierwszemu pacjentowi terapii w ramach badania klinicznego fazy II w pr…
Polish 2.8 KB
2025-07-31 08:50
Legal Proceedings Report
Otrzymanie od FDA protokołu z podsumowaniem spotkania pre-IND - Content (PL)
Polish 2.0 KB
2025-07-29 14:05
Regulatory News Service
Otrzymanie Certyfikatu Dobrej Praktyki Wytwarzania od Głównego Inspektora Farma…
Polish 1005 bytes
2025-06-23 15:30
Regulatory News Service
Warunkowe przyznanie europejskiego patentu dotyczącego metody ekspansji ex vivo…
Polish 884 bytes
2025-06-13 15:56
Foreign Filer Report
Rejestracja spółki zależnej Immuthera w USA - Content (PL)
Polish 784 bytes
2025-05-21 12:30
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Zgromadze…
Polish 2.3 KB

Automate Your Workflow. Get a real-time feed of all Poltreg S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Poltreg S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Poltreg S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Benitec Biopharma Inc. Logo
Develops ddRNAi gene therapies to silence genes causing chronic, life-threatening diseases.
United States of America
BNTC
BeOne Medicines Ltd. Logo
Develops innovative and accessible cancer treatments for patients worldwide.
United States of America
ONC
BGM Group Ltd. Logo
A pharma holding co. making APIs & TCM derivatives via bio-fermentation and extraction.
United States of America
BGM
Bicara Therapeutics Inc. Logo
Developing first-in-class, dual-action bifunctional therapies for solid tumor patients.
United States of America
BCAX
BICYCLE THERAPEUTICS PLC Logo
Developing novel bicyclic peptide medicines to precisely target hard-to-treat cancers.
United States of America
BCYC
BIFIDO. Co. Ltd Logo
Biotech firm specializing in microbiome R&D for functional foods and cosmeceuticals.
South Korea
238200
BioAge Labs, Inc. Logo
Develops therapies for metabolic diseases like obesity by targeting the biology of human aging.
United States of America
BIOA
BioArctic Logo
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
Sweden
BIOA
BioAtla, Inc. Logo
Developing safer, conditionally active antibody therapies for solid tumor cancers.
United States of America
BCAB
BioCardia, Inc. Logo
Developing regenerative cell therapies for cardiovascular and pulmonary diseases.
United States of America
BCDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.